Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab for adult ocular myasthenia gravis
jRCT2051260102Phase 3Recruiting
- Sponsor
- UCB
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing rozanolixizumab with placebo (2 arms). Primary endpoint: Change from baseline at Day 43 in MGII ocular score (Patient-Reported Outcome part). Started Aug 2026; status: recruiting.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2051260102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260102.